Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10916230 | Nuclear Medicine and Biology | 2005 | 11 Pages |
Abstract
We are interested in imaging cell death in vivo using annexin V radiolabeled with 124I. In this study, [124I]4IB-annexin V and [124I]4IB-ovalbumin were made using [124I]N-hydroxysuccinimidyl-4-iodobenzoate prepared by iododestannylation of N-hydroxysuccinimidyl-4-(tributylstannyl)benzoate. [124I]4IB-annexin V binds to phosphatidylserine-coated microtiter plates and apoptotic Jurkat cells and accumulates in hepatic apoptotic lesions in mice treated with anti-Fas antibody, while [124I]4IB-ovalbumin does not. In comparison with 124I-annexin V, [124I]4IB-annexin V has a higher rate of binding to phosphatidylserine in vitro, a higher kidney and urine uptake, a lower thyroid and stomach content uptake, greater plasma stability and a lower rate of plasma clearance. Binding of radioactivity to apoptotic cells relative to normal cells in vitro and in vivo appears to be lower for [124I]4IB-annexin V than for 124I-annexin V.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Bronwen Dekker, Heather Keen, David Shaw, Lynn Disley, David Hastings, John Hadfield, Andrew Reader, Donald Allan, Peter Julyan, Alastair Watson, Jamal Zweit,